摘要
目的探讨抗血管新生药物在慢性髓系白血病靶向治疗中的应用价值。方法本次研究将我院2013年6月~2014年8月收治的48例慢性髓系白血病患者分为研究组和一般组,予以一般组伊马替尼治疗,在一般组的基础上予以研究组重组人血管内皮抑制素治疗。结果治疗2个疗程后,研究组的治疗总有效率为87.5%,高于一般组的62.5%（P〈0.05）。治疗3个疗程后,研究组的治疗总有效率为95.8%,高于一般组的66.8%（P〈0.01）。治疗结束后随访1年,研究组的病死率为16.7%,低于一般组的50.0%（P〈0.05）。结论抗血管新生药物在慢性髓系白血病患者靶向治疗中的应用,可有效改善患者临床治疗效果和预后。
Objective To investigate the application value of anti angiogenesis drugs in the treatment of chronic myeloid leukemia. Methods 48 cases of patients with chronic myeloid leukemia in our hospital from June 2013 to August 2014 were divided into study group and general group, which were treated with imafinib in general group. Results Alter 2 courses of treatment, the total effective rate was 87.5% in the study group, which was higher than that in the general group of 62.5% （P〈0.05）. After 3 courses of treatment, the total effective rate of the study group was 95.8%, which was significantly higher than that of the general group （P〈0.01）. At the end of the treatment, two groups of patients were followed up for 1 years, the moaality rate of the study group was 16.7%, lower than the general group of 50% （P〈0.05）. Conclusion The application of anti angiogenesis drugs in the treatment of patients with chronic myeloid leukemia can effectively improve the clinical therapeutic effect and prognosis.
出处
《中国继续医学教育》
2015年第22期93-94,共2页
China Continuing Medical Education
关键词
慢性髓系白血病
靶向治疗
抗血管新生药物
应用价值
Chronic myeloid leukemia, Target therapy, Anti angiogenesis drugs, Application value
